13 results about "Human neutrophil" patented technology

The present invention relates to recombinant C. acnes and method of producing thereof. The present invention provides a human neutrophil gelatinase-associated lipocalin (NGAL) protein derived from a recombinant bacterium and its uses thereof. Particularly, the present invention relates to the use of NGAL protein obtained from a recombinant bacterium in the treatment of acne vulgaris or as a cosmetical composition. Provided herein are also recombinant bacterium expressing NGAL protein and their uses.

The disclosed methods are directed to preparing and detecting polypeptides using neutrophil elastase, such as human neutrophil elastase. The polypeptides are optionally denatured, reduced, and / or alkylated before being subjected to a first digestion. A second digestion comprises the use of neutrophil elastase, such as human neutrophil elastase. The prepared fragments are then analyzed chromatographically, electrophoretically, or spectrometrically, or a combination of these methods. The methods are especially useful for the preparation of therapeutic polypeptides for analysis, especially those that are not easily cleaved, such as some bi-specific T-cell engager (BiTE®) molecules.

The invention discloses nucleotide of fusion protein for coding neutrophil elastase and application of the nucleotide. A nucleotide sequence for coding the fusion protein is as shown in SEQ ID NO. 8; the nucleotide sequence of mRNA (messenger ribonucleic acid) for coding the fusion protein is as shown in SEQ ID NO. 12; the fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment. The mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the wild type ELANE can achieve a tumor elimination effect only by complex intratumor injection. According to the mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the ELANE fusion protein, tumor elimination in a mouse body can be realized only through intramuscular injection administration, the operation is simpler and more convenient, and the mRNA preparation is beneficial to treatment of scattered and tiny tumor focuses in the body.

The present disclosure describes novel dihydropyrimidopyrimidines which are useful as proteinase 3 (PR3) and / or human neutrophil elastase (HNE) inhibitors. The dihydropyrimidopyrimidine compounds of the disclosure can be fused with another heteroaromatic ring. The compounds are believed to be useful for treatment of inflammatory diseases, including chronic obstructive pulmonary disease.

The invention relates to a fluorescent reagent for detecting human neutrophil apolipoprotein and application of the fluorescent reagent. The fluorescent reagent comprises a fluorescent reagent I and a fluorescent reagent II, the fluorescent reagent I and the fluorescent reagent II are encapsulated in polymethyl methacrylate microspheres and have single-excitation dual-emission characteristics, the excitation light is near 345 nm, the emission light is near 445 nm and 615 nm respectively, and the emission light of 615 nm is later than the emission light of 445 nm. The reagent, a buffer solution and human neutrophil apolipoprotein antibody protein form a detection kit, and the detection kit is used for detecting neutrophil apolipoprotein in fresh human venous blood. The preparation method comprises the steps of fluorescent microsphere preparation, antibody preparation, microsphere surface activation, coupling reaction, sealing, cleaning, storage and the like. The detection method comprises the following steps: taking serum, mixing the fluorescent microsphere compound, detecting a fluorescence value and calculating the protein concentration. The method improves the sensitivity and accuracy of a detection system, is simple and convenient to operate and short in time consumption, and has a wide application prospect.

The objective was to develop a novel neutrophil elastase measurement method that can measure neutrophil elastase with high sensitivity. [Solution] A method for measuring human neutrophil elastase in a sample is provided, comprising contacting the sample with two or more antibodies or antigen-binding fragments thereof that recognize different epitopes on a complex with human neutrophil elastase. A reagent or kit for immunological measurement of human neutrophil elastase is also provided, comprising two or more antibodies or antigen-binding fragments thereof that recognize different epitopes on a complex with human neutrophil elastase and its inhibitor.

The application provides preparation and application of a diagnostic monoclonal antibody for a new epitope of human neutrophil lipocalin (HNL). Two new HNL protein conformation epitopes and one new HNL linear epitope are designed and provided, and an anti-HNL antibody with higher binding affinity and better binding specificity is screened to combine the new epitopes. The anti-HNL antibody of the application can be used for preparation of an HNL detection reagent and kit, and has higher sensitivity and specificity when used for detecting HNL protein in a sample, and can be applied to distinguishing bacterial infection and viral infection.

The invention discloses a fusion protein of neutrophil elastase as well as a preparation method and application of the fusion protein. The fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment; the amino acid sequence of the fusion protein is as shown in SEQ ID NO.8. The use of ELANE is limited due to intolerance to serine protease inhibitors (such as alpha-1-antitrypsin, A1AT). The optimized ELANE fragment and the optimized A2M fragment are connected to form the fusion protein, the fusion protein has high enzymatic activity, the tolerance to A1AT is greatly improved, and 83.3% of enzyme activity can still be maintained after the fusion protein acts for 2 hours through high-concentration A1AT (19200 nM). The fusion protein can efficiently eliminate mouse tumors and is safe to mice. The fusion protein is simple in preparation process and easy to industrially amplify, and a new strategy is provided for tumor treatment.

The invention belongs to the technical field of medicine development, and discloses a compound with a function of degrading human neutrophil elastinase (NE) as well as a preparation method and application of the compound. Specifically, the invention discloses a compound with a general formula (I), a pharmaceutically acceptable salt, a stereoisomer and a prodrug molecule thereof, the compound has an effect of degrading target protein NE in cells, and the compound shows wide pharmacological activity related to degradation of the target protein NE. The compound can be used for preparing medicines for preventing / treating target protein NE overexpression diseases or symptoms.

The present disclosure relates to a method for detecting the presence or absence of homodimer human neutrophil lipocalin (HNL) in a sample. Methods, kits, and devices for establishing the presence of or excluding a bacterial infection are also provided. The present invention allows for accurate and reliable detection of bacterial infections and monitoring of bacterial infections as well as monitoring of the efficacy of antibacterial treatments by specifically detecting homodimers HNL using a specific combination of specific monoclonal antibodies.

This invention discloses the application of ubiquitin-specific protease USP4 in the treatment of acute lung injury / acute respiratory distress syndrome (ARDS). Analysis of the GEO database revealed elevated USP4 levels in ARDS patients; in vitro stimulation of human neutrophils with LPS showed increased USP4 expression levels; experiments confirmed that the USP4 inhibitor Vialinin A effectively treats ARDS and significantly improves mouse survival; adenovirus inhibition of USP4 expression in the lungs effectively alleviates ARDS; and USP4 deficiency in the hematopoietic system effectively alleviates ARDS. This invention is the first to propose the application of USP4 as a target in screening drugs for the treatment of ARDS, providing a new target and a novel treatment strategy for clinical practice.

The invention provides preparation and application of a monoclonal antibody for diagnosis aiming at a human neutrophil lipocalin (HNL) neoepitope. Two new HNL protein conformational epitopes and a new HNL linear epitope are designed and provided, and the anti-HNL antibody which is combined with the new epitopes and has higher binding affinity and better binding specificity is obtained through screening. The anti-HNL antibody disclosed by the invention can be used for preparing an HNL detection reagent and a kit, has higher sensitivity and specificity when being used for detecting HNL protein in a sample, and can be applied to distinguishing bacterial infection and virus infection.

The invention provides an anti-ELR + CXC chemotactic factor antibody or an antigen binding fragment thereof as well as a preparation method and application of the anti-ELR + CXC chemotactic factor antibody. The ELR + CXC chemotactic factor antibody or the antigen binding fragment thereof. The ELR + CXC chemotactic factor is selected from one or more of CXCL1, CXCL2, CXCL3 and CXCL8. According to the application, the antibody which is specifically combined with the ELR + CXC chemotactic factor strongly related to the disease is screened out, the antibody can block a signal channel of the ELR + CXC chemotactic factor, ERK phosphorylation and human neutrophil chemotactic activity are blocked, and a new feasible scheme is provided for treatment of inflammation, immune diseases and cancers.